{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
PMV Pharmaceuticals, Inc.
Is PMV Pharmaceuticals, Inc. technically bullish or bearish?
As of June 2, 2025, PMV Pharmaceuticals, Inc. shows a mildly bearish trend with mixed signals from moving averages and indicators, suggesting a cautious outlook.
Who are in the management team of PMV Pharmaceuticals, Inc.?
As of March 2022, the management team of PMV Pharmaceuticals, Inc. is led by Dr. David Mack, who is the President, Chief Executive Officer, Co-Founder, and Director.
What does PMV Pharmaceuticals, Inc. do?
PMV Pharmaceuticals, Inc. is a precision oncology company developing small molecule therapies targeting p53 mutations. It has a market cap of $56.63 million and reported a net profit loss of $17 million as of March 2025.
How big is PMV Pharmaceuticals, Inc.?
As of Jun 18, PMV Pharmaceuticals, Inc. has a market capitalization of 56.63 million, with net sales of 0.00 million and a net profit of -60.88 million over the latest four quarters. The company reported shareholder's funds of 176.08 million and total assets of 191.29 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
